Your browser doesn't support javascript.
loading
Treatment outcome and persistence of repigmentation from narrow-band ultraviolet B phototherapy in vitiligo.
Silpa-Archa, Narumol; Weerasubpong, Puncharas; Junsuwan, Natchaya; Yothachai, Punyanut; Supapueng, Orawan; Wongpraparut, Chanisada.
Affiliation
  • Silpa-Archa N; a Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University , Bangkok , Thailand.
  • Weerasubpong P; a Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University , Bangkok , Thailand.
  • Junsuwan N; a Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University , Bangkok , Thailand.
  • Yothachai P; a Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University , Bangkok , Thailand.
  • Supapueng O; b Division of Clinical Epidemiology, Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University , Bangkok , Thailand.
  • Wongpraparut C; a Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University , Bangkok , Thailand.
J Dermatolog Treat ; 30(7): 691-696, 2019 Nov.
Article in En | MEDLINE | ID: mdl-30474443
ABSTRACT

Background:

Narrow-band ultraviolet B (NB-UVB) phototherapy is a mainstay treatment in vitiligo. However, data relative to repigmentation outcome, prognostic factors, and duration of repigmentation are limited.

Objectives:

To investigate the quantitative repigmentation outcome of NB-UVB phototherapy in vitiligo, the factors associated with favorable prognosis after NB-UVB, and the duration of repigmentation after NB-UVB discontinuation. Materials and

methods:

Medical records of vitiligo patients who underwent NB-UVB phototherapy at Department of Dermatology, Siriraj Hospital during 2012 to 2016 were retrospectively reviewed. Repigmentation was assessed using Vitiligo Area Scoring Index (VASI) score.

Results:

Fifty-eight patients were included. All patients received NB-UVB phototherapy twice to three times weekly for a median duration of 12 months. Forty-two patients had nonsegmental vitiligo (NSV), and 16 had segmental vitiligo (SV). NSV and SV demonstrated overall improvement in VASI score of -50.0%±31.0% and -40.0%±28.3%, respectively. Factors predictive of good outcome included type of vitiligo, lesion location, disease duration before NB-UVB, and duration and total number of NB-UVB treatments. Persistence of repigmentation was observed in approximately 80% of cases at one year after discontinuation of NB-UVB.

Conclusion:

NB-UVB phototherapy is an effective treatment for vitiligo, especially NSV. Repigmentation persisted in 80% of patients at 1 year after cessation of phototherapy.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Phototherapy / Ultraviolet Therapy / Vitiligo / Skin Pigmentation Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: J Dermatolog Treat Year: 2019 Type: Article Affiliation country: Thailand

Full text: 1 Database: MEDLINE Main subject: Phototherapy / Ultraviolet Therapy / Vitiligo / Skin Pigmentation Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: J Dermatolog Treat Year: 2019 Type: Article Affiliation country: Thailand